GLP-1/GIP/Glucagon triple agonist, CAS 2381089-83-2, 99% purity, COA available
We excluded 1) those with diagnoses of AF, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, mechanical valve, hyperthyroidism, or mitral stenosis before or on the index date, 2) those with cardiac events (i.e., myocardial infarction, percutaneous intervention, valve/bypass surgery) in the preceding 3 months, 3) those currently receiving antiarrhythmic medications (e.g., amiodarone, dronedarone, flecainide, propafenone, or dofetilide) on the index date, 4) those who used insulin within one year prior or on the index date, and 5) those who do not have hemoglobin A1C (HbA1c) within one year prior or on the index date (eFigure 1)
YZH, YH, and HL analyzed the results
Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: A double-blind, placebo-controlled clinical trial
But there are no completed randomized trials in women yet, so it is not a proven treatment
Higher liver pathology is documented in individuals with O
